Apixaban, a direct oral anticoagulant, has emerged over the past few years because it is
considered to have a low risk of drug‐drug interactions compared to vitamin K antagonists …

Aim The direct oral anticoagulants (DOAC) have similar half-lives, but the dosing regimen
varies between once daily (QD) or twice daily (BID). For some prescribers, the QD regimen …

Introduction Non-small cell lung cancer (NSCLC) is often caused by molecular alterations
that can be detected by predictive biomarkers including mutations or amplifications of …

Direct oral anticoagulants (DOACs) have rapidly become the drug class of choice for
anticoagulation therapy in secondary care. It is known that gastrointestinal hemorrhage are …

Direct oral anticoagulants (DOACs) are increasingly used and are an important cornerstone
in antithrombotic therapy. Adverse drug reactions (ADRs) such as bleedings have only …

Rivaroxaban has become an alternative to vitamin K antagonists, which are considered to
be at higher risk of drug-drug interactions (DDI) and more difficult to use. However, DDI do …

Background The aim of this study was to characterize the risk of a delayed intracranial
hemorrhage (ICH) in trauma patients on direct-acting oral anticoagulants (DOACs). Methods …

Abstract The SAMe-TT2R2 score predicts optimal long-term oral Vitamin K Antagonist (VKA)
anticoagulation for homogenous Caucasian and homogenous Asian populations for non …

Abstract Objective Direct oral anticoagulants (DOACs) were developed to avoid the
limitations of vitamin K antagonists (VKAs). DOACs are associated with a greater incidence …

Vitamin K is essential for the carboxylation of the vitamin K-dependent proteins that are
responsible for the suppression of matrix calcification. The use of vitamin K antagonists …